Verrucous Carcinoma

Based on promising progression-free survival (PFS) interim analysis, trial to continue and an optimized number of patients to be randomized in the trial Management to host webcast presentation of the interim results today, November 2, 2022 at 6 p.m. CET / 1 p.m. EST STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News: Transgene SA (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that following an interim analysis of its randomized controlled Phase II clinical study comparing TG4001 in combination with avelumab to avelumab alone in patients with HPV16-positive anogenital tumors (NCT: 03260023), the Independent Data Monitoring Committee (IDMC) has recommended the study continue. Based on positive signals observed in the interim analysis, the trial is now expected to enroll an additional 66 patients, for a total trial size of 120 patients compared to the previously announced target of 150 patients. Transgene anticipates the last patient to be randomized in the trial in H1 2024. Hedi Ben Brahim, CEO, and Dr. Maud Brandely, Chief Medical Officer, MD, PhD, will host an analyst and investor call to discuss the interim analysis at 6:00 pm CET (1:00 pm EST) today (see details below). The Phase II study is evaluating TG4001, an investigational therapeutic cancer vaccine, in combination with avelumab compared to avelumab alone in patients with HPV16-positive anogenital tumors without liver metastases, through a continuing collaboration with the alliance of Merck KGaA, Darmstadt, Germany, and Pfizer, which is supplying avelumab. “We are very pleased with the outcome of this interim analysis,” said Hedi Ben Brahim, Chief Executive Officer of Transgene. “The IDMC’s recommendation to continue the study reinforces our confidence in TG4001, which follows promising data from our earlier Phase Ib/II trial. This also enables us to reduce the number of patients randomized in the trial. We are looking forward to completing this trial in H1 2024 and communicating its results when they are available. We expect that positive final results from this trial will allow us to launch a registration trial to further confirm the benefit of our therapeutic vaccine candidate. TG4001 aims to provide a new solution to patients who currently have very limited treatment options.” The interim analysis was triggered per protocol, by a predefined number of PFS events. Based on the interim results, the IDMC’s objective was to provide a recommendation on the continuation of the trial and on the final sample size using adaptive sample size re-estimation modeling approach. To date, the treatment has been well tolerated. Adverse events are consistent with previous observations made in the Phase Ib/II trial. TG4001 is based on a MVA (Modified Vaccinia Ankara) vector, which is engineered to express HPV16 antigens (E6 & E7) and interleukin 2 (IL-2). TG4001 is designed to alert the immune system specifically to cells presenting the HPV16 E6 and E7 antigens that can be found in HPV16-related tumors and to induce a specific cellular immune response against these cancer cells. Phase II trial aims to show superiority of TG4001 + avelumab over avelumab monotherapy The trial is enrolling patients in the USA and in Europe (France and Spain). It focuses on patients with recurrent or metastatic HPV16-positive anogenital cancer without liver metastases, including cervical, vulvar, vaginal, penile, and anal cancer. Patients are randomized to either receive the combination regimen of the therapeutic vaccine TG4001 and avelumab or avelumab alone. The primary endpoint of the trial is progression-free survival (PFS) according to RECIST 1.1. Secondary endpoints include objective response rate (ORR), disease control rate (DCR), overall survival (OS) and a series of immunological parameters. A conference call in English is scheduled today, on November 2, 2022, at 6 p.m. CET / 1 p.m. EST. Webcast link to English language conference call: Participant telephone numbers: France: +33 (0) 1 70 37 71 66 United Kingdom: +44 (0) 33 0551 0200 United States: +1 212 999 6659 Confirmation code: Transgene A replay will be available on the Transgene website ( ) following the live event. About the trial The multi-center, open label, randomized Phase II trial (NCT03260023) is designed to compare the efficacy of the combination of TG4001 and avelumab versus avelumab alone in patients with advanced, recurrent and/or metastatic HPV16-positive anogenital cancers who have disease progression after a maximum of one line of systemic treatment, or who are not eligible for first-line chemotherapy. Prof. Christophe Le Tourneau, M.D., PhD, Head of the Department of Drug Development and Innovation (D3i) at the Curie Institute, is the Principal Investigator of the study. The trial is being conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE), which are providing avelumab for the trial. Avelumab is co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer Inc. Transgene will continue to be the sponsor of the trial and conduct the trial. Avelumab is not approved alone or in combination for the treatment of HPV16-positive anogenital tumors in any region. Patients will receive TG4001 at the dose of 5x107 pfu, SC, weekly for 6 weeks, every 2 weeks up to six months, and every 12 weeks thereafter, in combination with avelumab or avelumab alone at 800 mg, IV every two weeks, until disease progression. The primary endpoint of the trial is progression-free survival (PFS) according to RECIST 1.1. Secondary endpoints include objective response rate (ORR), disease control rate (DCR), overall survival (OS) and other immunological parameters. The trial will enroll 120 patients. About the Phase Ib/II data of TG4001 + avelumab (single arm trial) The combination of TG4001 and avelumab demonstrated anti-tumor activity (22% ORR) in patients with previously treated recurrent and/or metastatic HPV-related cancers (including patients with oropharyngeal cancers and anogenital cancers). Presence of liver metastases had a profound impact on the outcome in terms of ORR and PFS. In patients without liver metastases, an ORR of 32%, a median PFS of 5.6 months and a median OS of 13.3 months were achieved. The treatment induced HPV-specific T-cell responses and was associated with increased levels of immune cell infiltration in the tumors and expression of genes associated with activation of the immune system. The results from the Phase Ib/II parts of the trial combining TG4001 with avelumab in HPV16-positive recurrent and/or metastatic malignancies have been updated in a R&D day held in September 2022 by Transgene. A first set of data had been presented at SITC 2020 and ESMO IO 2020 [1,2]. About TG4001 TG4001 is an investigational therapeutic vaccine based on a non-propagative, highly attenuated Vaccinia vector (MVA), which is engineered to express HPV16 antigens (E6 & E7) and an adjuvant (IL-2). TG4001 is designed to have a two-pronged antiviral approach: to alert the immune system specifically to cells presenting the HPV16 E6 and E7 antigens, that can be found in HPV16-related tumors, and to further stimulate the infection-clearing activity of the immune system through interleukin 2 (IL-2). TG4001 has been administered to more than 350 individuals, demonstrating good safety and promising efficacy results [1, 2,]. Its mechanism of action and good safety pro TG4001 an excellent candidate for combinations with other therapies in HPV-mediated solid tumors. About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells. The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform). With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca. Additional information about Transgene is available at: . Follow us on Twitter: @TransgeneSA Transgene disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document, available on the AMF website ( ) or on Transgene’s website ( ). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. References [1] Le Tourneau et al. “TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity.” 2020 SITC Annual Meeting, 9-11 November 2020, Poster presentation [2] Le Tourneau et al. “TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironment (TME) and drives antitumor responses in Human PapillomaVirus (HPV)+ malignancies.”2020 ESMO IO meeting, 12 December 2020, mini-oral presentation

Netherlands-based Leyden Laboratories closed a €40 Million Series A financing led by GV (formerly Google Ventures) that will be used to develop the Leyden Labs’ platform and portfolio of product candidates. Leyden Labs uses its platform to target commonalities of viral families to protect against many viruses simultaneously as opposed to vaccines that typically protect against a specific virus variant. Its intranasal product candidates will be self-administrable, providing people with the freedom to protect themselves instantaneously from infection and prevent transmission. Funds will also be used to expand the company’s team. In addition to GV, the Series A was supported by F-Prime Capital, Casdin Capital, LLC and Brook Byers. David Schenkein, general partner at GV, and Stephen Knight, president and managing partner at F-Prime, will both join the board of directors of Leyden Laboratories. eTheRNA – Belgium-based eTheRNA immunotherapies NV was awarded a €6.9 million TIGER grant from the EU Commission that will be used to accelerate development of a novel, potentially best-in-class therapeutic mRNA cancer vaccine for treating recurrent/metastatic Human Papillomavirus strain 16 positive (HPV16+) cancers such as head and neck cancer, cervical cancer, anogenital cancer. Early data suggests mRNA may play a key role in treating cancers and autoimmune diseases with potential mRNA market of approximately $37 billion in 2030. RDIF – The Russian Direct Investment Fund partnered with India’s Virchow Biotech Private Limited to produce in the country up to 200 million doses per year of Sputnik V, the Russian-developed vaccine against coronavirus. In addition to the agreement with Vircow, RDIF also released a survey that showed its vaccine was one of the most recognizable in the world. According to the RDIF, the YouGov survey results showed 54% of the 9,417 respondents from nine countries considered Russia the most trusted vaccine producer alongside the United States. RDIF said its Sputnik V vaccine was also the most recognizable vaccine to the respondents. Of those surveyed, 74% said they knew the name of Russia’s vaccine. Sputnik V is also among top-two most preferred vaccines, just after the one produced by Pfizer and BioNTech, RDIF said in its release. Insightful Science – U.K.-based Insightful Science, a software company, will acquire Dotmatics, a cloud-based scientific R&D data management platform. By integrating Insightful Science’s software applications into Dotmatics cloud-first enterprise data management solution, the company will provide an end-to-end scientific research platform. This combination further improves laboratory efficiency and accelerates the pace of scientific innovation by facilitating more rapid data access, analysis and exchange between scientists around the world, the company said. Amolyt Pharma – Based in France, Amolyt announced positive data from the first cohorts of the single ascending dose portion of its Phase I clinical trial evaluating the company’s lead clinical candidate, AZP-3601, for the treatment of hypoparathyroidism. The data demonstrated a significant, sustained increase in blood calcium levels for at least 24 hours following a single administration of AZP-3601. Relief Therapeutics – Switzerland’s RELIEF and Acer Therapeutics entered into a collaboration for worldwide development and commercialization of ACER-001. ACER-001 is a proprietary powder formulation of sodium phenylbutyrate (NaPB) designed to be both taste-masked and immediate release. An ACER-001 pre-NDA meeting with the U.S. FDA is scheduled to occur in the second quarter of 2021. Acer expects to receive official meeting minutes approximately 30 days after the meeting. PhoreMost Ltd. -- PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to “Drugging the Undruggable” disease targets, completed an oversubscribed £33 million (about $46 million) Series B investment round. The funding will be used to progress PhoreMost’s preclinical ‘Allosteric PLK1’ collaboration with Sentinel Oncology into the clinic in 2022. The programme is initially targeted towards Glioma. PhoreMost will also progress multiple additional internal first-in-class drug discovery programmes across both oncology and aging therapeutic indications. The funding round was led by BGF, the UK’s most active growth economy investor, and included new investors XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventures. Existing investors Parkwalk Advisors, Morningside Ventures, and Jonathan Milner also contributed. Dunad Therapeutics – Also based in the U.K., startup Dunad Therapeutics emerged this week to develop next-generation small molecule therapeutics based on its highly differentiated, tuneable and targeted protein degradation technology. Dunad, secured initial financing from Epidarex Capital, a transatlantic venture firm that specializes in seeding and building exceptional early-stage life science companies. Dunad’s unique small molecule platform induces targeted degradation of disease-causing and often undruggable proteins via direct modification of the target using mono-valent small molecules. The company’s novel molecular approach is fully tuneable to be exquisitely selective and underpinned by a target-class agnostic mechanism of action that is distinct from other targeted protein degradation technologies. Dunad said its platform has the potential to unlock access to orally bioavailable and CNS-accessible degrader therapeutics and expand the frontiers of protein degradation targets. Step Pharma – Oncology and autoimmune disease focused Step Pharma, based in France, closed a €35 million Series B funding round. The proceeds will be used to advance Step Pharma’s lead proprietary CTPS1 inhibitor, STP938, into clinical development for the treatment of T-cell malignancies. In addition, Step Pharma will use the funding to advance development of CTPS1 inhibitors in other hematological malignancies and solid tumors. CTPS1 (cytidine triphosphate synthase 1) is an enzyme that plays a critical role in DNA synthesis, cell division and proliferation but whose function is highly selective to certain cell types, in particular proliferating T cells, making it an ideal target for drug development. The financing round was led by Sunstone Life Science Ventures and supported by existing investors Kurma Partners, Pontifax and Bpifrance, which reinvested through its Innovative Biotherapies and Rare Diseases fund and InnoBio 2 fund. Ilya Pharma – Sweden’s Ilya Pharma released new data from its clinical study of chronic wound treatment, ILP100. Ilya’s ILP100 gene therapy shortens healing time by on average six days, the company said. Additionally, scar volume also reduced by 30% through on-site production and delivery of key chemokine CXCL12 by transformed lactic acid bacteria. Ilya hopes to initiate a Phase II study later this year, if the ongoing COVID-19 pandemic allows. InteRNA Technologies – microRNA (miRNA)-focused InteRNA Technologies, based in the Netherlands, announced that preclinical data investigating the company’s lead candidate, INT-1B3, have been published in the peer-reviewed journals Molecular Therapy Nucleic Acids and Oncotarget. INT-1B3 is a mimic of the tumor suppressor miRNA-193a-3p and has the potential to address multiple hallmarks of cancer at the same time. The published results include data from tumor cell lines and experimental tumor models and support the high therapeutic potential of INT-1B3 in solid tumor indications.